Skip to main content
. 2020 Sep 11;15:403. doi: 10.1186/s13018-020-01919-9

Table 1.

General characteristic of the included studies

Author Country No. of patients (PRP vs HA) Age (years, PRP vs HA) Sex (male, PRP vs HA) BMI (PRP vs HA) Radiographic classification (PRP vs HA) Follow-up (m)
0 I II III IV
Ahmad 2018 [22] Egypt 45/44 56.2/56.8 14/14 NS 0/0 8/7 17/19 20/18 0/0 6
Buendia-Lopez 2018 [23] Spain 33/32 56.2/56.6 16/15 24.9/24.9 0/0 18/18 15/14 0/0 0/0 12
Cerza 2012 [24] Italy 60/60 66.5/66.2 25/28 NS 0/0 21/25 24/22 15/13 0/0 6
Cole 2017 [20] USA 49/50 55.9/56.8 28/20 27.4/29 0/0 3/0 26/27 20/22 0/0 12
Di Martino 2019 [25] Italy 85/82 52.7/57.5 53/47 27.2/26.8 NS 60
Duymus 2017 [26] Turkey 33/34 60.4/60.3 1/1 27.6/28.4 0/0 0/0 22/24 21/10 11/0 12
Filardo 2015 [19] Italy 94/89 53.3/57.6 60/52 26.6/26.9 NS NS NS NS NS 12
Gormeli 2017 [27] Turkey 39/39 53.7/53.5 16/17 28.7/29.7 0/0 26/30 13/14 6
Huang 2019 [28] China 40/40 54.5/54.8 25/19 25.2/24.5 0/0 40/40 0/0 0/0 12
Li 2011 [29] China 15/15 57.6/58.2 6/7 24.3/21.0 0/0 6/6 2/3 4/3 3/3 6
Lin 2019 [17] China 31/29 61.2/62.5 9/10 24.0/26.3 5/6# 16/14# 10/9# 12
Louis 2018 [30] France 24/24 53.2/48.5 14/11 25.6/27.0 0/0 0/0 24/24 6
Montanez-Heredia 2016 [31] Spain 27/26 66.3/61.5 12/9 29.0/30.4 0/0 5/2 10/9 12/15 0/0 6
Paterson 2016 [32] Australia 11/10 49.9/52.7 8/7 27.9/28.9 0/0 0/0 11/10 0/0 3
Raeissadat 2015 [33] Iran 77/62 56.9/61.1 8/15 28.2/27.0 0/0 5/0 34/29 29/23 9/10 12
Sanchez 2012 [34] Spain 89/87 60.5/58.9 43/42 27.9/28.2 45/43# 32/33# 12/11# 6
Su 2018 [35] China 25/30 54.2/53.1 11/12 28.2/28.7 0/0 0/0 16/13 11/12 0/0 6
Vaquerizo 2013 [36] Spain 48/48 62.4/64.8 16/22 30.7/31.0 NS NS 12
Yu 2018 [37] China 104/88 46.2/51.5 50/48 NS NS NS 12
Tavassoli 2019 [38] Iran 28/27 63.2/66.0 5/8 28.4/28.9 21/22 35/32 3

NS not stated, PRP platelet-rich plasma, HA hyaluronic acid

# Ahlbäck grade, and the rest were K–L grades